公开(公告)号：US20110183336A1

公开(公告)日：2011-07-28

申请号：US12767725

申请日：2010-04-26

申请人： JOE W. GRAY ,  DEBOPRIYA DAS ,  WEN-LIN KUO ,  NICHOLAS J. WANG ,  RICHARD M. NEVE ,  PAUL T. SPELLMAN ,  JANE FRIDLYAND ,  KOEI CHIN ,  ZHI HU

发明人： JOE W. GRAY ,  DEBOPRIYA DAS ,  WEN-LIN KUO ,  NICHOLAS J. WANG ,  RICHARD M. NEVE ,  PAUL T. SPELLMAN ,  JANE FRIDLYAND ,  KOEI CHIN ,  ZHI HU

IPC分类号： C12Q1/68 ,  G01N33/573 ,  G01N33/53 ,  C07H21/02 ,  C07H21/00 ,  C07K16/32

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178

摘要： Methods of-identifying a basal or luminal phenotype of a cell, comprising detecting expression of one or more of a set of predictive biomarker genes or proteins that identify the cell as having a basal or luminal cancer subtype and compositions for treating identified basal or luminal cancers.

摘要翻译： 鉴定细胞的基底或管腔表型的方法，包括检测一组或多个鉴定细胞的预测性生物标志物基因或蛋白质的表达，所述基因或腔表型具有基底或管腔癌症亚型，以及用于治疗所鉴定的基底或腔内癌症的组合物 。

公开(公告)号：US08404829B2

公开(公告)日：2013-03-26

申请号：US11814798

申请日：2006-01-19

申请人： Joe W. Gray ,  Yinghui Guan ,  Wen-Lin Kuo ,  Jane Fridlyand ,  Gordon B. Mills

发明人： Joe W. Gray ,  Yinghui Guan ,  Wen-Lin Kuo ,  Jane Fridlyand ,  Gordon B. Mills

IPC分类号： C07H20/04 ,  C07H21/02 ,  A61K48/00

CPC分类号： G01N33/57449 ,  G01N2800/44 ,  G01N2800/52

摘要： Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described.

摘要翻译： 可以开发癌症标志物以检测特征在于凋亡抑制基因如侵袭性癌症的表达增加的特征。 发现人染色体区域中的基因8q24,11q13,20q11-q13被扩增，表明在诸如卵巢癌等疾病中的体内耐药性。 扩增级别的诊断和评估显示要扩增的某些基因（包括PVT1）可用于预测低存活率的卵巢癌患者患者反应和耐药性差的结果。 通过鉴定涉及基因组序列的复发性畸变，拷贝数和/或基因表达与某些疾病和癌症（特别是卵巢癌）的生存期降低有关，某些基因被认为是高度优先的治疗靶点。 描述了抑制这些基因之一的抑制剂的治疗剂，PVT1，具有低存活率的卵巢癌患者中的靶药物抗性。

公开(公告)号：US20090203051A1

公开(公告)日：2009-08-13

申请号：US12330386

申请日：2008-12-08

申请人： Joe W. Gray ,  Jane Fridlyand ,  Richard Neve ,  Paul Spellman ,  Koei Chin ,  Zhi Hu ,  Frederic Waldman

发明人： Joe W. Gray ,  Jane Fridlyand ,  Richard Neve ,  Paul Spellman ,  Koei Chin ,  Zhi Hu ,  Frederic Waldman

IPC分类号： A61K31/7088 ,  C12Q1/68 ,  C40B30/04 ,  G01N33/574 ,  G01N33/68 ,  C12N5/06

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136

摘要： Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.

摘要翻译： 癌症标志物被开发用于检测特征在于凋亡抑制基因如侵袭性癌症的表达增加的疾病。 在乳腺癌基因组拷贝数和基因表达的基因组分析中，发现人染色体区域中的66个基因，8p11,11q13,17q12和20q13被扩增。 显示扩增的基因的扩增水平的诊断和评估可用于预测患者在乳腺癌中的反应和耐药性的结果。 通过鉴定涉及基因组序列的复发性畸变，拷贝数和/或基因表达与某些疾病和癌症特别是乳腺癌中的存活时间减少有关，某些基因被认为是高度优先的治疗靶点。 这些基因的抑制剂将是治疗这些非反应性癌症的有用治疗方法。

公开(公告)号：US20120077694A1

公开(公告)日：2012-03-29

申请号：US13243712

申请日：2011-09-23

申请人： Joe W. Gray ,  Jane Fridlyand ,  Richard Neve ,  Paul Spellman ,  Koei Chin ,  Zhi Hu ,  Frederic Waldman

发明人： Joe W. Gray ,  Jane Fridlyand ,  Richard Neve ,  Paul Spellman ,  Koei Chin ,  Zhi Hu ,  Frederic Waldman

IPC分类号： C40B30/04 ,  G01N33/566 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136

摘要： Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.

摘要翻译： 癌症标志物被开发用于检测特征在于凋亡抑制基因如侵袭性癌症的表达增加的疾病。 在乳腺癌基因组拷贝数和基因表达的基因组分析中，发现人染色体区域中的66个基因，8p11,11q13,17q12和20q13被扩增。 显示扩增的基因的扩增水平的诊断和评估可用于预测患者在乳腺癌中的反应和耐药性的结果。 通过鉴定涉及基因组序列的复发性畸变，拷贝数和/或基因表达与某些疾病和癌症特别是乳腺癌中的存活时间减少有关，某些基因被认为是高度优先的治疗靶点。 这些基因的抑制剂将是治疗这些非反应性癌症的有用治疗方法。

公开(公告)号：US20080312096A1

公开(公告)日：2008-12-18

申请号：US11814798

申请日：2006-01-19

申请人： Joe W. Gray ,  Yinghui Guan ,  Wen-Lin Kuo ,  Jane Fridlyand ,  Gordon B. Mills

发明人： Joe W. Gray ,  Yinghui Guan ,  Wen-Lin Kuo ,  Jane Fridlyand ,  Gordon B. Mills

IPC分类号： C40B30/04 ,  C12Q1/68 ,  G01N33/53 ,  C12N15/63 ,  C07H21/00 ,  C07H21/02

CPC分类号： G01N33/57449 ,  G01N2800/44 ,  G01N2800/52

摘要： Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described.

摘要翻译： 可以开发癌症标志物以检测特征在于凋亡抑制基因如侵袭性癌症的表达增加的特征。 发现人染色体区域中的基因8q24,11q13,20q11-q13被扩增，表明在诸如卵巢癌等疾病中的体内耐药性。 扩增级别的诊断和评估显示要扩增的某些基因（包括PVT1）可用于预测低存活率的卵巢癌患者患者反应和耐药性差的结果。 通过鉴定涉及基因组序列的复发性畸变，拷贝数和/或基因表达与某些疾病和癌症（特别是卵巢癌）的生存期降低有关，某些基因被认为是高度优先的治疗靶点。 描述了抑制这些基因之一的抑制剂的治疗剂，PVT1，具有低存活率的卵巢癌患者中的靶药物抗性。